abstract details

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

Clinical course over two years in patients with early non-radiographic axial spondyloarthritis and ankylosing spondylitis without anti-tumor necrosis factor α treatment: Results from the GErman SPondyloarthritis Inception Cohort (GESPIC)

Author information

Poddubnyy D1, Haibel H1, Braun J2, Rudwaleit M3, Sieper J1. Arthritis Rheumatol. 2015 May 27. doi: 10.1002/art.39225. [Epub ahead of print]

Abstract

OBJECTIVE:he aim of this analysis was to investigate the clinical course of disease over two years in patients with non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS).

METHODS:In total, 303 patients with axSpA (158 with AS and symptom duration ≤10 years, and 145 with nr-axSpA and symptom duration ≤5 years) with available follow-up data over 2 years not treated with tumor necrosis factor (TNF) α blockers were included.

RESULTS:Patients with nr-axSpA and AS did not differ in BASDAI at any time point during follow-up, BASFI was significantly higher in AS at baseline only, but spinal mobility was generally more impaired in AS patients. Patients with AS had significantly higher C-reactive protein (CRP) levels at all time-points. Accordingly, ASDAS was significantly higher in the AS subgroup at 2 out of 4 time-points. If patients having a BASDAI≥4 plus an elevated CRP at baseline were analyzed over time there were no substantial differences in the proportions of patients who had achieved low disease activity on at least 2 time-points during follow up if a clinical definition of low disease activity was used (BASDAI<4 or ≤2: 38% or 13% for nr-axSpA and 36% or 15% for AS, respectively) but numerically more patients in the nr-axSpA reached low-disease activity if definitions were applied which included CRP (BASDAI<4 plus normal CRP or ASDAS inactive disease: 25% or 13% for nr-axSpA and 10% or 3% for AS).

CONCLUSION:Patients with nr-axSpA and AS not treated with TNF α blockers demonstrated a similar clinical disease course over 2 years. Patients with nr-axSpA reached a status of low disease activity more frequently compared to AS if outcome parameters including CRP were used.